The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between ...
A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...
Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.
Stocktwits on MSN
BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company
The clarification from the German biotech company comes on the heels of a Bloomberg report that Pfizer is considering selling ...
The Hearty Soul on MSN
Study Suggests Possible Link Between Pfizer COVID-19 Vaccine and Vision-Related Eye Conditions
Bagpipers claim world record with AC/DC's 'It's a Long Way to the Top' Archaeologists Accidentally Discovered the Oldest Gun Ever Found in America $450 million "American Colossus" would be taller than ...
Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...
There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...
The financial markets responded immediately, with BioNTech shares declining as much as 5% in pre-market trading. This partnership has historically formed the cornerstone of BioNTech's commercial ...
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies ...
Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating ...
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...
Valneva's trajectory was significantly altered in August when the U.S. Food and Drug Administration (FDA) suspended the license for its Chikungunya vaccine IXCHIQ®, citing safety concerns. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results